HNWAG
CYCN icon

High Net Worth Advisory Group’s Cyclerion Therapeutics CYCN Stock Holding History

High Net Worth Advisory Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50
Closed -$1K – 691
2022
Q2 		$1K Hold
50
– – ﹤0.01% 646
2022
Q1 		$1K Buy
50
+25
+100% +$602 ﹤0.01% 657
2021
Q4 		$1K Buy
+25
New +$1.18K ﹤0.01% 666

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

High Net Worth Advisory Group's CYCN Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of Cyclerion Therapeutics (CYCN) in Q3 2022, closing a stake of 50 shares — an estimated $1K sold.

High Net Worth Advisory Group first reported a position in CYCN in Q4 2021 and held it in 3 quarters. The position peaked at $1K in Q2 2022. 37 funds tracked by Wall St. Rank hold CYCN as of Q3 2022.

  • High Net Worth Advisory Group reported no remaining Cyclerion Therapeutics position as of Q3 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 50 Cyclerion Therapeutics shares in Q3 2022, an estimated $1K.
  • High Net Worth Advisory Group first reported a position in Cyclerion Therapeutics in Q4 2021 and held it in 3 quarters.
  • High Net Worth Advisory Group's Cyclerion Therapeutics position peaked at $1K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.